We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Technique Catalogs Lymphoma-Linked Genetic Variations

By LabMedica International staff writers
Posted on 17 Jan 2013
A novel approach has been devised to sort out random mutations in genes associated with lymphoma, and the proteins produced by the genes could be tested to see how they performed. More...


Antigen receptor signaling to nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB), is essential for normal lymphocyte activation, but is dysregulated in several types of lymphoma.

Scientists at Johns Hopkins School of Medicine (Baltimore, MD, USA) made copies of the caspase recruitment domain family, member 11 (CARD11) gene in a way that made random mutations likely. The CARD11 protein plays a key role in signaling the presence of infection, which leads infection-fighting white blood cells to grow and divide.

The investigators then used the faulty copies to make mutant proteins, and tested the ability of those proteins to trigger the signaling reaction that is CARD11's specialty. This allowed them to find to which mutations increased the protein's activity and by how much and this information could then be compared to emerging data about CARD11 mutations found in human lymphomas. They noted that CARD11 is part of the NF- κB signaling pathway, a target of some cancer therapies
.
Joel Pomerantz, PhD, an associate professor in the Johns Hopkins School of Medicine's Institute for Cell Engineering, and senior author of the study said "Our goal was to correlate various mutations with potential to promote lymphoma. We imagine eventually being able to correlate response to a particular therapy with a particular mutation." The cancers called lymphomas, affect about 75,000 patients in the United States of America each year. The study was published in the January 2013 issue of the journal Molecular and Cellular Biology.

Related Links:

Johns Hopkins School of Medicine




New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.